BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types. BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity. At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Its mechanisms of action are multifaceted and have been studied extensively in over 100 animal studies. A central aspect of its activity involves upregulation of growth factor expression, including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and their receptors. This pro-angiogenic activity helps explain its remarkable wound-healing and tissue-repair properties observed across multiple tissue types. BPC-157 also interacts with the nitric oxide (NO) system in a complex, context-dependent manner. It can rescue NO production when it is pathologically inhibited and can attenuate excessive NO when it is overproduced, suggesting a modulatory rather than unidirectional effect. Research by Sikiric et al. has demonstrated that BPC-157 interacts with the dopaminergic system and may counteract both the acute and chronic effects of dopaminergic agents, pointing to direct CNS activity. At the gastrointestinal level, BPC-157 maintains mucosal integrity by promoting granulation tissue formation and angiogenesis within lesion sites. It has shown cytoprotective effects against NSAID-induced gastric damage, ethanol-induced lesions, and stress ulcers in numerous rodent models. The peptide appears to modulate the FAK-paxillin pathway, which is critical for cell migration and adhesion during wound repair.

In rodent studies, BPC-157 is typically administered at 10 mcg/kg or 10 ng/kg, delivered intraperitoneally or locally at the injury site. Oral administration has also been studied for gastrointestinal applications. No human clinical trial data is currently published.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.